home / stock / arfxf / arfxf news

ARFXF News and Press, Amorfix Life Sciences Ltd From 10/21/20

Stock Information
Company Name: Amorfix Life Sciences Ltd
Stock Symbol: ARFXF
Market: OTC
Website: promisneurosciences.com
Menu
ARFXF ARFXF Quote ARFXF Short ARFXF News ARFXF Articles ARFXF Message Board
Get ARFXF Alerts

News, Short Squeeze, Breakout and More Instantly...
ARFXF - ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab

TORONTO and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...
ARFXF - ProMIS Neurosciences' Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference

ProMIS’ proprietary drug discovery and development platform highlighted for ability to create novel antibod ies , diagnostic s and vaccine candidates for neurodegenerative diseases TORONTO and CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE...

ARFXF - ProMIS Neurosciences to develop multivalent vaccine for Alzheimer's disease

TORONTO and CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disea...

ARFXF - ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference

TORONTO and CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disea...
ARFXF - ProMIS Neurosciences Announces Second Quarter 2020 Results

TORONTO and CAMBRIDGE, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the...

ARFXF - ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer's disease

TORONTO and CAMBRIDGE, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets (peptide antigens) on the molecular surface of complex, misfolded proteins, and BC Neuroimmunology Lab (BCNI)...

ARFXF - ProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders

TORONTO and CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...
ARFXF - ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19

TORONTO and CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, and its collaborator BC Neuroimmunology Lab Inc. (BCNI), have c...

ARFXF - ProMIS Neurosciences and collaborative team receive Supercluster Award supporting avoidance of future pandemics by new strains of the COVID-19 virus

TORONTO and CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique core technology to predict novel targets on the molecular surface of complex proteins, together with a team of commercial and academic collaborators, ha...

ARFXF - ProMIS Neurosciences Chairman's Update details new programs from expanded use of novel technology platform

TORONTO and CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disease...
Previous 10 Next 10